Bolt - BOLT

Option chain shows key data for Bolt Biotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bolt Biotherapeutics.

Bolt Biotherapeutics (NASDAQ:BOLT) Stock, Option Chain

Bolt Biotherapeutics

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Screenshot 2024-12-06 at 6.41.42 PM

Emerging Markets

Commodities

Movers & Shakers

Markets

BOLT

PACIFIC RIM COBALT CORP by Pacific Rim Cobalt Corp.

PCRCF

Bolt Metals Corp. (CSE: BOLT) Makes A Power Move: Strategic Acquisition Of Copper-Silver Assets Signals Expansion

movers

News

Intraday Update

Movers

AEMD

ARQT

AWIN

BCRX

BSFC

CABA

CDRO

CRKN

CSLR

CTNT

DELL

DLPN

EDBL

FFIE

GWAV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INTZ

IRBT

JFBR

KOSS

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MNDY

NOVA

NSYS

NTRB

NVAX

OPRX

PEGY

PLSE

PXLW

RIVN

RSKD

SINT

SLNA

SPCE

SPWR

VRPX

VTSI

YTEN

Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Prague,cz,-27,April,2023:,Logo,On,Accenture,Headquarters,In,Prague.

Downgrades

Analyst Ratings

Trading Ideas

AMRK

This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics Inc

Bolt Metals Corp

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings Inc

Press Releases

BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Penny Stocks

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT

Management

Bolt Biotherapeutics Announces Changes to its Board of Directors

Health Care

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Earnings

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

ABVC BioPharma

BioVie

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

Equillium

Ernexa Therapeutics

GlycoMimetics

Geovax Labs

Imunon

IN8bio

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Kairos Pharma

Leap Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

BiomX

Polyrizon

Portage Biotech

Rallybio

SAB Biotherapeutics

Synlogic

Unity Biotechnology

Stifel

Leerink Partners

SVB Leerink

Morgan Stanley

Bolt Technology

Comments

Bolt Biotherapeutics

Bolt Biotherapeutics (BOLT) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell